Journal of SAFOMS

Register      Login

VOLUME 6 , ISSUE 1 ( January-June, 2018 ) > List of Articles

CASE REPORT

Primary Fallopian Tube Carcinoma

D Sumangala Devi

Keywords : Hydrops tubae profluens, Primary fallopian tube carcinoma, Transcoelomic exfoliation

Citation Information : Devi DS. Primary Fallopian Tube Carcinoma. J South Asian Feder Menopause Soc 2018; 6 (1):79-81.

DOI: 10.5005/jp-journals-10032-1144

Published Online: 01-06-2018

Copyright Statement:  Copyright © 2018; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Primary fallopian tube carcinoma (PFTC) is a rare tumor. It is seen in the age group between 40 and 60 years. It has resemblance to epithelial ovarian cancer, both clinically and histologically. Only 5% of patients show symptoms of profuse watery vaginal discharge (hydrops tubae profluens). Ultrasound, computerized tomography, and magnetic resonance imaging (MRI) can help in arriving at a diagnosis. Tumor marker cancer antigen (CA)-125 levels can be used as a diagnostic and prognostic marker to detect recurrence. The most common histopathology is serous papillary. Transcoelomic exfoliation of cells is the most common mode of spread of the tumor. Other modes of spread include contiguous invasion, hematogenous and transluminal dissemination. The PFTC is managed surgically like epithelial ovarian cancer. Adjuvant chemotherapy is also similar to epithelial ovarian cancer.


PDF Share
  1. Riska A, Leminen A, Pukkala E. Sociodemographic determinants of incidence of primary fallopian tube carcinoma, Finland 1953-97. Int J Cancer 2003 May;104(5):643-645.
  2. Inal MM, Hanhan M, Pilanci B, Tinar S. Fallopian tube malignancies: experience of Social Security Agency Aegean Maternity Hospital. Int J Gynecol Cancer 2004 Jul-Aug;14(4):595-599.
  3. Ajithkumar TV, Minimole AL, John MM, Ashok kumar OS. Primary fallopian tube carcinoma. Obstet Gynecol Surv 2005 Apr;60(4):247-252.
  4. Hefler LA, Rosen AC, Graf AH, Lahousen M, Klein M, Leodolter S, Reinthaller A, Kainz C, Tempfer CB. The clinical value of serum concentrations of cancer antigen 125 in patients with primary fallopian tube carcinoma: a multicenter study. Cancer 2000 Oct;89(7):1555-1560.
  5. Kurjak A, Kupesic S, Sparac V, Kosuta D. Three-dimensional ultrasonographic and power Doppler characterization of ovarian lesions. Ultrasound Obstet Gynecol 2000 Sep;16(4): 365-371.
  6. Baekeland M, Jorunn Nesbakken A, Kriestensen GB, Tropé CG, Abeler VM. Carcinoma of the fallopian tube. Cancer 2000 Nov;89(10):2076-2084.
  7. Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, Vermorken JB, Torri V, Mangioni C, Pecorelli S, et al; International Collaborative Ovarian Neoplasm 1; European Organisation for Research and Treatment of Cancer Collaborators-Adjuvant ChemoTherapy in Ovarian Neoplasm. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003 Jan;95(2):105-112.
  8. Gemignani ML, Hensley ML, Cohen R, Venkatraman E, Saigo PE, Barakat RR. Paclitaxel-based chemotherapy in carcinoma of the fallopian tube. Gynecol Oncol 2001 Jan;80(1):16-20.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.